Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating pembrolizumab, an immunotherapy, in children and teens with advanced melanoma, solid tumors, and lymphomas that are advanced, relapsed, or refractory. The study aims to determine if different doses of pembrolizumab can reduce or eliminate these cancers. Enrollment restrictions have been applied over time for certain age groups and tumor types. Participants receive pembrolizumab intravenously at a starting dose of 2 mgkg up to 200 mg every three weeks. Different groups include children with melanoma, solid tumors, relapsed refractory classical Hodgkin lymphoma, MSI-H solid tumors, TMB-H solid tumors, and high-risk resected melanoma. Enrollment for some groups has been closed with protocol amendments. Participants will be monitored for tumor response using established cancer criteria over up to two years. Researchers will assess objective response rates, duration of response, progression-free survival, adverse events, and drug tolerability. Safety and disease status are tracked during and after treatment, with study participation lasting until February 2028.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.
Actively Recruiting
Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate KarXT in adults with Bipolar-I disorder experiencing acute manic or mixed episodes. The study focuses on assessing how well KarXT works compared to a placebo during a three-week inpatient treatment period. Participants must be hospitalized due to their acute symptoms, and the study includes a total duration of up to seven weeks covering screening, treatment, and safety follow-up. Participants are randomly assigned to receive either KarXT or a placebo with flexible dosing during the inpatient phase. The main goal is to observe changes in manic symptoms using the Young Mania Rating Scale over three weeks. The study monitors safety and efficacy through standardized psychiatric assessments and follows participants closely during the inpatient stay. During the trial, participants will undergo regular evaluations including psychiatric ratings and clinical global impressions to track symptom changes and treatment response. The study includes initial screening, a three-week double-blind treatment period while hospitalized, and a safety follow-up period to monitor participants health. The total participation time does not exceed seven weeks.
Actively Recruiting
The research investigates the mental and physical health effects of war-related traumatic events on children, adolescents, and their parents in Israel, focusing on psychotherapy outcomes and dropout rates. It addresses gaps in knowledge about distress following the October 7th, 2023 multi-regional conflict, exploring how parental mental health influences childrens well-being and therapy engagement. The study uses both retrospective and prospective methods to understand these impacts and therapy predictors. The study includes two phases a retrospective analysis of electronic health records from Clalit Health Services covering children and adolescents aged 6-18 who received outpatient psychotherapy between 2015 and 2024, and a prospective study involving ongoing psychotherapy cases at Shalvata Mental Health Centers Crisis Intervention Unit. Data includes demographics, diagnoses, therapy attendance, and therapy outcome measures. The prospective phase assesses pre-treatment and within-treatment factors such as therapeutic alliances, expectations, and symptoms over seven weeks with repeated assessments. Participants will undergo various assessments including psychological symptom checklists, somatic symptom scales, and therapeutic alliance questionnaires completed by patients, caregivers, and therapists at baseline and during therapy. Retrospective data will analyze dropout rates and mental health trends before and after therapy. The study will monitor health services utilization up to two years post-therapy start. Consent procedures accommodate parental involvement, and safety protocols address participant distress. Overall participation duration varies by phase and therapy course.
Actively Recruiting
Researchers are studying the relationship between psychotherapy expectations and psychological distress among adults receiving mental health care in psychiatric departments or community clinics, along with their therapists. This observational study takes place at Shalvata Mental Health Center and aims to understand how patients and therapists expectations relate to treatment outcomes over time. Participants include patients treated in closed and open hospitalization units and ambulatory clinics, as well as their therapists. Data collection occurs at four time points baseline, two weeks, four weeks, and eight weeks or at discharge. Questionnaires are completed using the Qualtrics platform, with research staff assisting hospitalized patients and face-to-face interactions at community clinics for initial assessments. During the study, patients and therapists complete multiple scales measuring symptoms, expectations, and clinical impressions. Patients fill out questionnaires at baseline and follow-up points, while therapists also provide input. Suicidal thoughts reported during face-to-face sessions trigger immediate notification to therapeutic staff. The study monitors symptom changes and treatment expectations over an eight-week period or until discharge.
Actively Recruiting
Researchers are evaluating whether adding cannabidiol CBD to existing antipsychotic treatment improves response in people experiencing their first episode of psychosis who have not responded well or at all to their initial antipsychotic medication. This randomized, double-blind, placebo-controlled trial also aims to confirm the safety of CBD in this group. The study includes various clinical assessments and explores biomarkers to predict treatment outcomes, with optional blood, stool, and neuroimaging samples collected at certain sites. Participants will be randomly assigned to receive either CBD oral solution, dosed at 500mg twice daily or adjusted by weight if under 50 kg, or a matching placebo, both taken alongside their current antipsychotic medication for six weeks. The trial compares these two groups to assess the effect of CBD as an addition to standard treatment during this period. During the study, participants will undergo clinical assessments including symptom scales and functioning evaluations, with primary measurement focusing on changes in psychosis symptoms after six weeks. Biomarkers are assessed at baseline and six weeks to explore links to symptom improvement. Safety will be monitored throughout treatment and for 30 days afterward, with participants adherence and health status regularly evaluated. Total participation spans the treatment duration plus follow-up assessments extending up to 58 weeks for some measures.
Actively Recruiting
Researchers are investigating how immune-inflammatory biomarkers interact with the oxytocin system to influence the development of posttraumatic stress disorder PTSD and its response to psychotherapy. This observational study includes adults with PTSD symptoms and aims to understand biological factors that may affect treatment resistance and recovery. The study is sponsored by Shalvata Mental Health Center and focuses on trauma-related distress and psychotherapy outcomes. Participants will undergo weekly psychotherapy sessions for 12 weeks, with scheduled assessments of oxytocin and inflammatory markers such as IL-1b2, IL-6, and TNF-b1 in saliva before and after sessions 1, 6, and 12. Self-report questionnaires measuring PTSD symptoms, depression severity, and general anxiety will be completed after these sessions. The study also evaluates psychological resilience and the working alliance between patient and therapist. Throughout the study, participants will provide saliva samples and complete surveys to monitor changes in biological markers and mental health symptoms. Researchers will measure the relationship between these biomarkers and treatment progress over the 12 to 16 week period depending on treatment duration. The study aims to provide insights into factors influencing psychotherapy responsiveness, with ongoing safety and symptom monitoring.